CANCER IMMUNOLOGY (CI) Over the past decade, immunotherapy has emerged as an established modality that is revolutionizing the treatment of many cancers. The Cancer Immunology (CI) Research Program has focused on genetically manipulating T cells, applying new principles of synthetic biology, and combining engineered T cells with small molecules and antibodies to broaden the applications and improve the safety and efficacy of adoptive immunotherapy. Despite the success achieved with immunologic approaches in treating some malignancies, major gaps exist in our current understanding of the complex relationship between progressing tumors and host immunity, and these must be understood and overcome to achieve the potential of immunotherapy in many common cancers. The CI program will focus on systematically tackling these barriers to eradicating tumors using a variety of immunotherapeutic modalitie alone and in combination.
The specific aims of CI are (1) to develop effective and safe cellular immunotherapies for adult and pediatric hematologic malignancies and solid tumors, (2) to identify and overcome the barriers to immune-mediated tumor eradication using clinical specimens and preclinical models, (3) to translate discoveries in basic immunology and synthetic biology to novel clinical applications in cancer immunotherapy. The Cancer Immunology (CI) program currently has 39 members from 11 departments and divisions and 4 Consortium institutions. Nineteen members have primary appointments at Fred Hutch, 12 members at University of Washington, and 8 members at Seattle Children?s. Fourteen new faculty members joined this program in the last cycle. The current research support of CI members is $23.4M (direct costs) in research grant funding, of which $4.4M (19%) is from the NCI and $7.8M (33%) is peer reviewed. The Cancer Immunology program published a total of 470 papers in the last grant period, of which 14% were intra- programmatic, 49% were inter-programmatic, and 50% had external co-authors. Program members have utilized all 12 of the Consortium Shared Resources. This P30 grant also assists this program by providing administrative and logistical support for CI meetings, pilot funding for new research projects, and recruitment resources for new faculty.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-46
Application #
10125973
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
46
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843
Briant, Katherine J; Sanchez, Janeth I; Ibarra, Genoveva et al. (2018) Using a Culturally Tailored Intervention to Increase Colorectal Cancer Knowledge and Screening among Hispanics in a Rural Community. Cancer Epidemiol Biomarkers Prev 27:1283-1288
Baker, K Scott; Syrjala, Karen L (2018) Long-term complications in adolescent and young adult leukemia survivors. Hematology Am Soc Hematol Educ Program 2018:146-153
Miller, Chris P; Tsuchida, Connor; Zheng, Ying et al. (2018) A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia 20:610-620
Paulson, K G; Voillet, V; McAfee, M S et al. (2018) Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun 9:3868
Puronen, Camille E; Cassaday, Ryan D; Stevenson, Philip A et al. (2018) Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biol Blood Marrow Transplant 24:2211-2215
Gavvovidis, Ioannis; Leisegang, Matthias; Willimsky, Gerald et al. (2018) Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clin Cancer Res 24:3644-3655
Rosenthal, Elisabeth A; Shirts, Brian H; Amendola, Laura M et al. (2018) Rare loss of function variants in candidate genes and risk of colorectal cancer. Hum Genet 137:795-806
Verboon, Jeffrey M; Decker, Jacob R; Nakamura, Mitsutoshi et al. (2018) Correction: Wash exhibits context-dependent phenotypes and, along with the WASH regulatory complex, regulates Drosophila oogenesis (doi:10.1242/211573). J Cell Sci 131:
Witzky, Anne; Hummels, Katherine R; Tollerson 2nd, Rodney et al. (2018) EF-P Posttranslational Modification Has Variable Impact on Polyproline Translation in Bacillus subtilis. MBio 9:

Showing the most recent 10 out of 1267 publications